⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MESO News
Mesoblast Limited American Depositary Shares
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
globenewswire.com
MESO
Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight
prnewswire.com
CYTK
NVO
BCDA
AZN
BMY
LLY
MESO
ASMB
LXRX
VTRS
AMGN
IRWD
NVS
MRK
Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight
prnewswire.com
MESO
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
globenewswire.com
MESO
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
globenewswire.com
MESO
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
globenewswire.com
MESO
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
globenewswire.com
MESO
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
prnewswire.com
IART
MESO
EOLS
BVS
CNXU
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
globenewswire.com
MESO
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
globenewswire.com
MESO